Anticoagulation Therapy in Children

Shoshana Revel-Vilk; Anthony K. C. Chan

doi:10.1055/s-2003-42592

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29(4): 425-432
DOI: 10.1055/s-2003-42592

Anticoagulation Therapy in Children

Shoshana Revel-Vilk¹ , Anthony K.C. Chan²

¹Lecturer, Pediatric Hematology/ Oncology Unit Hadassah Hebrew University Hospital Jerusalem, Israel
²Department of Pediatrics, McMaster University, Hamilton, and Department of Pathology and Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Ontario, Canada

Abstract

ABSTRACT

Thromboembolic events (TEs) in children are rare but are becoming a recognized cause of morbidity and mortality, particularly in children with serious underlying primary conditions such as congenital heart disease, cancer, or prematurity. Neonates, infants, and adolescents are most at risk for developing TEs among children, and the presence of a central venous line or intra-arterial catheter is the most significant risk factor for TEs in children. Hemostatic differences between children and adults affect both the pathophysiology of the thrombotic process and the response to anticoagulant therapy. In this article, we focus on the impact of the developmental hemostatic system on responses to anticoagulants in children. The most commonly used anticoagulants in children are unfractionated heparin, low-molecular-weight heparins, and warfarin. Minimal experience exists with the use of the new antithrombotic agents in children. As the anticoagulant treatment used for TEs in children is largely adopted from clinical trials performed in adult populations, well-designed prospective trials are required to establish the optimal therapy for children with TEs.

KEYWORDS

Thrombosis - thromboembolism - children - anticoagulants - heparin

Full Text

References

REFERENCES

1 Andrew M, David M, Adams M. et al . Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood . 1994; 83 1251-1257
2 van Ommen H C, Heijboer H, Büller H R, Hirasing R A, Heijmans H SA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr . 2001; 139 676-681
3 Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutanous cardiac catheterization in children. Circulation . 1974; 50 565-569
4 deVeber G, Andrew M, Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl J Med . 2001; 345 417-423
5 Schoenberg B S, Mellinger J F, Schoenberg D F. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival. Neurology . 1978; 28 763-768
6 Broderick J, Talbot T G, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. J Child Neurol . 1993; 8 250-255
7 deVeber G, Monagle P, Chan A. et al . Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol . 1998; 55 1539-1543
8 Andrew M, David M, deVeber G, Brooker L A. Arterial thromboembolic complications in paediatric patients. Thromb Haemost . 1997; 78 715-725
9 Andrew M, Paes B, Milner R. et al . Development of the human coagulation system in the healthy premature infant. Blood . 1988; 72 1651-1657
10 Andrew M, Paes B, Milner R. et al . Development of the human coagulation system in the full-term infant. Blood . 1987; 70 165-172
11 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood . 1992; 8 1998-2005
12 Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost . 1994; 72 836-842
13 Schmidt B, Ofosu F, Mitchell L, Brooker L, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res . 1989; 25 405-408
14 Chan A K, Berry L R, Monagle P T, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost . 2002; 87 606-613
15 Hirsh J, Warkentin T E, Shaughnessy S G. et al . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest . 2001; 119 S64-S94
16 Vieira A, Berry L, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res . 1991; 63 85-98
17 Schmidt B, Buchanan M R, Ofosu F, Brooker L, Hirsh J, Andrew M. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Thromb Haemost . 1988; 60 289-292
18 Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan M R. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res . 1988; 52 517-527
19 Streif W, Mitchell L G, Andrew M. Antithrombotic therapy in children. Curr Opin Pediatr . 1999; 11 56-64
20 Andrew M, Marzinotto V, Massicotte P. et al . Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res . 1994; 35 78-83
21 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children. Chest . 2001; 119 S344-S370
22 Ranze O, Ranze P, Magnani H N, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients-a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr . 1999; 158(Suppl 3) S130-S133
23 Severin T, Sutor A H. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost . 2001; 27 293-299
24 Schmugge M, Risch L, Huber A R, Benn A, Fischer J E. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients (Abst). Pediatrics . 2002; 109 E10
25 Deitcher S R, Topoulos A P, Bartholomew J R, Kichus-Chrisant M R. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr . 2002; 140 264-266
26 Nguyen T N, Gal P, Ransom J L, Carlos R. Lepirudin use in a neonate with heparin-induced thrombocytopenia. Ann Pharmacother . 2003; 37 229-233
27 Avioli L. Heparin induced osteoporosis: an appraisal. Adv Exp Med Biol . 1975; 52 375-387
28 Dix D, Andrew M, Marzinotto V. et al . The use of low-molecular-weight heparin in pediatric patients: a prospective cohort study. J Pediatr . 2000; 136 439-445
29 Albisetti M, Andrew M. Low-molecular-weight heparin in children. Eur J Pediatr . 2002; 161 71-77
30 Weitz J I. Low-molecular-weight heparins. N Engl J Med . 1997; 337 688-698
31 Massicotte P, Adams M, Marzinotto V, Brooker L A, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr . 1996; 128 313-318
32 Vieira A, Ofosu F, Andrew M. The activity of low-molecular-weight heparin (CY222) in neonatal plasma. Thromb Haemost . 1991; 63 85-98
33 Andrew M, Ofosu F, Brooker L, Buchanan M. The comparison of the pharmacokinetics of a low-molecular-weight heparin in the newborn and adult pig. Thromb Res . 1989; 56 529-539
34 Massicotte P, Julian J A, Gent M. et al . An open-label randomized controlled trial of low-molecular-weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res . 2003; 109 85-92
35 Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low-molecular-weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr . 1999; 158(Suppl 3) S134-S139
36 Massicotte P, Julian J A, Gent M. et al . An open-label randomized controlled trial of low-molecular-weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res . 2003; 109 101-108
37 Revel-Vilk S, Sheratkumar A, Massicotte P. et al . Natural history of arterial and venous thrombosis in children treated with low-molecular-weight heparin. A longitudinal study by Doppler ultrasound (Abst). Blood . 2002; 100 279a
38 Hofmann S, Knoefler R, Lorenz N. et al . Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res . 2001; 103 345-353
39 Crowther M A, Berry L R, Mongale P T, Chan A K. Mechanism responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol . 2002; 116 178-186
40 Ryn-McKenna J, Cai L, Ofosu F A, Hirsh J, Buchanan M R. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost . 1990; 63 271-274
41 Tait D P. Does low-molecular-weight heparin cause bleeding?. Thromb Haemost . 1997; 78 1422-1425
42 Hirsh J, Dalen J E, Anderson D R. et al . Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest . 2001; 119 S8-S21
43 Massicotte P, Leaker M, Marzinotto V. et al . Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost . 1998; 80 570-574
44 Andrew M, Monagle P T, Brooker L. Developmental hemostasis: relevance to thromboembolic complication in pediatric patients. In: Andrew M, Monagle PT, Brooker L, eds. Thromboembolic Complications During Infancy and Childhood Hamilton, Ontario: BC Decker 2000: 5-46
45 Andrew M, Mongale P, Brooker L. Oral anticoagulant therapy in pediatric patients. In: Andrew M, Monagle PT, Brooker L, eds. Thromboembolic Complications During Infancy and Childhood Hamilton, Ontario: BC Decker 2000: 321-356
46 Buck M L. Anticoagulation with warfarin in infants and children. Ann Pharmacother . 1996; 30 1316-1322
47 Andrew M, Marzinotto V, Brooker L A. et al . Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost . 1994; 71 265-269
48 Tait R C, Ladusans E J, el-Metall M, Patel R G, Will A M. Oral anticoagulation in paediatric patients: dose requirements and complications. Arch Dis Child . 1996; 74 228-231
49 Streif W, Andrew M, Marzinotto V. et al . Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood . 1999; 94 3007-3014
50 Schmidt B, Andrew M. Report of Scientific and Standardization Subcommittee on Neonatal Hemostasis Diagnosis and Treatment of Neonatal Thrombosis. Thromb Haemost . 1992; 67 381-382
51 Marzinotto V, Monagle P, Chan A. et al . Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol . 2000; 21 347-352
52 Crowther M A, Julian J, McCarty D. et al . Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet . 2000; 356 1551-1553
53 Hooshang T, Capitanio M. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology . 1990; 176 728-730
54 Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long-term warfarin therapy (Abst). Thromb Haemost . 1999; 81(Suppl) 1333a
55 Ansell J E, Weitz J I, Comerota A J. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology (Am Soc Hematol Educ Program) . 2000; 266-284
56 Bauer K A. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost . 2002; 28(Suppl 2) 15-24
57 Markwardt F. Development of direct thrombin inhibitors in comparison with glycosaminoglycans. Semin Thromb Hemost . 2001; 27 523-530
58 Prisco D, Flaciani M, Antonucci E, Gensini G F. Hirudins for prophylaxis and treatment of venous thromboembolism. Semin Thromb Hemost . 2001; 27 543-549
59 Eriksson B I, Ekman S, Lindbratt S. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am . 1997; 79 326-333
60 Eriksson B I, Wille-Jørgensen P, Kalebo P. et al . A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med . 1997; 337 1329-1335
61 Schiele F, Lindgaerde F, Eriksson H. et al . Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicenter prospective dose-ranging randomized trial. Thromb Hemost . 1997; 77 834-838
62 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood . 2000; 96 846-851
63 Boshkov L K, Thomas G, Kirbi A. et al . Pharmacokinetics of argatroban infusion in a 6-month-old congenital cardiac patient with previously diagnosed heparin-induced thrombocytopenia (Abst). Blood . 2002; 100 278a
64 Herbert J M, Herault J P, Bernat A. et al . Biochemical and pharmacological properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide. Blood . 1998; 91 4197-4205
65 Turpie A GG, Bauer K A, Eriksson B I, Lassen M R. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet . 2002; 359 1721-1726
66 Elalamy I, Lecrubier C, Potevin F. et al . Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost . 1995; 74 1384-1385
67 Spanier T B, Chen J M, Oz M C. et al . Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1998; 116 860-869
68 Lee A, Agnelli G, Büller H. et al . Dose-response study of recombinant factor VIIa/tissue-factor inhibitor recombinant nematode anticoagulant protein C2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation . 2001; 104 74-78
69 Barrington K J. Umbilical artery catheters in the newborn: effect of catheter materials [review]. Cochrane Database Syst Rev 2000;CD000949 .
70 Pierce C M, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med . 2000; 26 967-972
71 Klement P, Du Y J, Berry L, Andrew M, Chan A K. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex. Biomaterials . 2002; 23 527-535